Despite five months of infliximab therapy, the patient’s symptoms persisted, with a Bath Ankylosing Spondylitis Disease Activity Index of 4 and an Ankylosing Spondylitis Disease Activity Score with CRP of 3.8, along with elevated CRP levels (37.4 mg/L). Here, CRP is linked to ankylosing spondylitis.